Indivior stock holds firm as analysts keep a moderate buy
Published on 08/26/2026 at 19:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Trading near the mid-30s
Indivior PLC (GB00BYZ0C031) traded at $35.97, with a market cap of $4.24 billion and a 52-week range of $22.22 to $42.81. The latest analyst snapshot also shows a P/E ratio of 12.89 and a beta of 0.86.
The setup is still being judged through earnings rather than hype. A recent analyst roundup put the average rating at Moderate Buy, with an average 12-month target of $45.1667, five buy ratings and two hold ratings.
Latest quarter still matters
The most recent quarter cited in the market data was reported on June 30, 2026, when Indivior posted $343.00 million in revenue and $5.75 in earnings per share. That quarter also carried a net margin of 26.65% and a negative return on equity of 283.11%.
For investors, the key comparison is simple: the current share price of $35.97 sits below the average 12-month target of $45.1667, while the 50-day moving average is $39.50 and the 200-day moving average is $35.99.
Analyst mix stays positive
The same research roundup says Craig Hallum reiterated a buy rating and a $53.00 target on August 4, 2026, while Barclays cut its price objective from $46.00 to $43.00 and kept an overweight view on August 5, 2026. Weiss Ratings also lowered its view from buy to hold.
That combination gives the stock a mixed but still constructive read: one fresh downgrade, one lower target, and one reiterated buy call. The broader consensus remains anchored by the same six-figure target spread that ranges from $43.00 to $53.00 in the latest reports.
Product and pipeline
Indivior's portfolio centers on addiction treatment, led by Suboxone, the buprenorphine and naloxone film, and Sublocade, the extended-release buprenorphine injection. Those products remain the core revenue drivers behind the latest quarterly figures.
What the tape shows
Indivior stock closed at $35.97 in the latest session cited by the market data, and the $4.24 billion valuation leaves it trading below the average broker target. The 52-week high of $42.81 is still the nearest clear reference point on the chart.
Fact box
Company: Indivior PLC
ISIN: GB00BYZ0C031
Ticker: INDV
Exchange: Nasdaq
Price (as of August 26, 2026): $35.97 USD
Market cap: $4.24 billion (as of August 26, 2026)
Sector / Industry: Healthcare / Drug Manufacturers - Specialty & Generic
Index membership: not stated in the cited sources
